Scientists at the University of Copenhagen's Center for Healthy Ageing have identified a compound that blocks the expression of a protein without which certain tumours cannot grow. This compound has the potential as an anticancer ...
Jan 24, 2013
0
0
A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which ...
Jan 23, 2013
0
0
Researchers at Imperial College London have shown that keeping healthy blood cells alive could be a more important tool in the fight against leukaemia than keeping cancerous cells at bay.
Jan 22, 2013
0
0
Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the ...
Dec 10, 2012
0
0
Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia (CML), a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant ...
Dec 9, 2012
0
0
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive ...
Dec 9, 2012
0
0
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Dec 9, 2012
0
0
(Medical Xpress)—In the first of its kind, a translational study undertaken at the Malaghan Institute of Medical Research has revealed that boosting the activity of a rare type of immune cell could be an effective way to ...
Nov 21, 2012
0
0
Researchers from John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's 50 best cancer centers, played an important role in a study published in the New England Journal of Medicine on October ...
Nov 20, 2012
0
0
(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).
Oct 26, 2012
0
0
